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Background: A phase I/II study and subsequent phase III study (MPACT) reported signiﬁcant correlations between
CA19-9 decreases and prolonged overall survival (OS) with nab-paclitaxel plus gemcitabine (nab-P + Gem) treatment for
metastatic pancreatic cancer (MPC). CA19-9 changes at week 8 and potential associations with efﬁcacy were investi-
gated as part of an exploratory analysis in the MPACT trial.
Patients and methods: Untreated patients with MPC (N = 861) received nab-P + Gem or Gem alone. CA19-9 was
evaluated at baseline and every 8 weeks.
Results: Patients with baseline and week-8 CA19-9 measurements were analyzed (nab-P + Gem: 252; Gem: 202). In an
analysis pooling the treatments, patients with any CA19-9 decline (80%) versus those without (20%) had improved OS
(median 11.1 versus 8.0 months; P = 0.005). In the nab-P + Gem arm, patients with (n = 206) versus without (n = 46) any
CA19-9 decrease at week 8 had a conﬁrmed overall response rate (ORR) of 40% versus 13%, and a median OS of 13.2
versus 8.3 months (P = 0.001), respectively. In the Gem-alone arm, patients with (n = 159) versus without (n = 43) CA19-
9 decrease at week 8 had a conﬁrmed ORR of 15% versus 5%, and a median OS of 9.4 versus 7.1 months (P = 0.404),
respectively. In the nab-P + Gem and Gem-alone arms, by week 8, 16% (40/252) and 6% (13/202) of patients, respect-
ively, had an unconﬁrmed radiologic response (median OS 13.7 and 14.7 months, respectively), and 79% and 84% of
patients, respectively, had stable disease (SD) (median OS 11.1 and 9 months, respectively). Patients with SD and any
CA19-9 decrease (158/199 and 133/170) had a median OS of 13.2 and 9.4 months, respectively.
Conclusion: This analysis demonstrated that, in patients with MPC, any CA19-9 decrease at week 8 can be an early
marker for chemotherapy efﬁcacy, including in those patients with SD. CA19-9 decrease identiﬁed more patients with sur-
vival beneﬁt than radiologic response by week 8.
Key words: CA19-9, pancreatic cancer, chemotherapy, nab-paclitaxel, MPACT
introduction
Metastatic pancreatic adenocarcinoma is one of the most aggres-
sive cancers, with <25% of patients alive 1 year after diagnosis
[1]. Carbohydrate antigen 19-9 (CA19-9), a Lewis blood group
antigen, is one of the most widely studied tumor markers in
patients with advanced pancreatic cancer [2–5] due to its utility in
determining prognosis and response to treatment [5–12]. In
general, higher versus lower CA19-9 levels at baseline and increasing
versus decreasing CA19-9 levels during therapy are associated with
worse prognosis [5, 6]. However, the predictive value of decreasing
CA19-9 levels during treatment for assessment of response and
survival has not been clearly deﬁned [6, 13]. In a pooled analysis
of six phase II trials of patients with advanced pancreatic cancer
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treated with gemcitabine (Gem)-containing chemotherapy, after
two cycles of treatment, ≤5% CA19-9 increase versus >5% in-
crease from baseline was predictive of improved outcome
[median overall survival (OS) 10.3 versus 5.2 months; P = 0.002]
[6]. nab-Paclitaxel plus gemcitabine (nab-P + Gem), a new stand-
ard treatment option for patients with advanced pancreatic
cancer, demonstrated superiority over Gem alone across all efﬁ-
cacy end points in a phase III trial, MPACT [14–16]. The phase
I/II study of nab-P + Gem that preceded MPACT reported a sig-
niﬁcant correlation between decreases in CA19-9 levels of ≥50%
versus <50% from baseline and improved survival (13.6 versus 6.5
months; P = 0.004) [16]. In a stepwise multivariate analysis, base-
line CA19-9 level was not an independent predictor of survival in
MPACT [17]; thus, an assessment to understand the dynamics of
CA19-9 changes during treatment was warranted. Here, we
report a detailed evaluation of the prespeciﬁed MPACT explora-
tory end points of changes in CA19-9 levels and correlations with
OS, progression-free survival (PFS), and overall response rate
(ORR).
methods
MPACT study design
The patients enrolled in and methods of the MPACT trial have been
described previously [14]. Key parameters and methods speciﬁc to this suba-
nalysis are described below. CA19-9 was evaluated at baseline and every 8
weeks up to week 40 per schedule. Patients could have had unscheduled
CA19-9 measurements.
patient population
For analyses that examined the change from baseline to nadir in CA19-9, all
patients who had a baseline and at least one postbaseline measurement were
included. For analyses that examined the change from baseline to week 8,
only patients who had a baseline and a week-8 measurement of CA19-9 were
included.
end points and statistical methods
reduction in CA19-9 from baseline at nadir. The proportions of
patients who achieved any, ≥20%, ≥60%, or ≥90% reduction from baseline
at nadir during the study were compared between the two treatment groups
using a χ2 test for each level of reduction.
predictive value of CA19-9 at week 8 (landmark) for OS, PFS,
and ORR. Patients who had a baseline and a week-8 measurement of
CA19-9 were included in the analyses to assess the predictive/prognostic
value of the percent change in ORR, PFS, and OS. The ORR, PFS, and OS
outcomes for various categories of changes in CA19-9 levels were evaluated
(including all patients with any increase, any decrease, and decreases ≥20%,
≥40%, ≥60%, or ≥90%). Treatment comparisons were conducted using a
stratiﬁed log-rank test for OS and PFS and a stratiﬁed Cox model for hazard
ratio (HR) based on geographic region (North America versus other),
Karnofsky performance status (70–80 versus 90–100), and the presence of
liver metastases (yes versus no). The stratiﬁcation was not applied when
there were fewer than 50 patients in either treatment group. The treatment
comparisons for ORR outcomes were performed using a χ2 test. Summaries
of survival statistics (e.g. median months of survival) were calculated using
the Kaplan–Meier method.
Per protocol, radiologic response by Response Evaluation Criteria In Solid
Tumors (RECIST v1.0) [18] was required to be conﬁrmed at an assessment at
least 4 weeks after the initial ﬁnding. A RECIST-deﬁned response at week 8
only, without a conﬁrmatory radiologic ﬁnding, was noted as ‘unconﬁrmed’.
kinetics of CA19-9 over time. The rate of decrease per week (i.e.
velocity slope) of CA19-9 during the ﬁrst 8 weeks of treatment was estimated
for each patient using a mixed-effects model (PROCMIXED in SAS 9.2), with
treatment as the ﬁxed effect and patient as the random effect. All observations
available from baseline to the end of cycle 1 (week 8) were included in the
model. Approximately 9% of the patients had at least one additional CA19-9
measurement between baseline and week 8. Given the large variability and the
skewness in the distribution of the CA19-9 values, log transformation was
applied to the CA19-9 measurements for this analysis.
results
characterization of CA19-9 decreases from baseline
CA19-9 levels at baseline and at least one time point postbase-
line were available for 512 patients (281 in the nab-P + Gem
arm and 231 in the Gem-alone arm); the change in CA19-9 from
baseline to nadir is described in supplementary Table S1, avail-
able at Annals of Oncology online.
Baseline and week-8 CA19-9 measurements were available for
454 patients (252 in the nab-P + Gem arm and 202 in the Gem-
alone arm); 82% and 79%, respectively, had any decrease in
CA19-9 at week 8 (Table 1). Baseline characteristics of patients
withweek-8 CA19-9 valueswere balanced between treatment arms
and representative of the MPACT study population (supplemen-
tary Table S2, available at Annals of Oncology online) [14].
pooled analysis: correlation between decrease in
CA19-9 levels from baseline to week 8 and OS
In a pooled analysis of all patients from the two treatment arms,
patients who had any (>0%) reduction in CA19-9 from baseline
to week 8 had a signiﬁcant improvement in OS compared with
those who did not have a reduction in CA19-9 (median OS 11.1
versus 8.0 months; P = 0.005; Table 2). Similar results were
demonstrated with ≥20%, ≥60%, and ≥90% reductions in
CA19-9 from baseline.
predictive and prognostic value of CA19-9 response
at week 8: landmark analysis
At week 8, improved efﬁcacy outcomes were observed in each
arm for any decrease in CA19-9 levels and at all cutoff levels of
CA19-9 decrease versus no change/any increase, with a statistic-
ally signiﬁcant beneﬁt in favor of nab-P + Gem versus Gem
alone (Table 3; Figure 1). In general, compared with patients
who met the individual cutoff values of any (>0%), ≥20%,
≥60%, or ≥90% decrease in CA19-9, patients who had no
change or any increase or a <20%, <60%, or <90% decrease in
CA19-9 at week 8 had lower conﬁrmed ORR, PFS, and OS
(Table 3). For example, in the nab-P + Gem arm, patients with
any CA19-9 decrease had longer OS than patients with no
change/any increase {median 13.2 versus 8.3 months; HR 0.53
[95% conﬁdence interval (CI) 0.36–0.78]; P = 0.001}. A similar
trend was observed in the Gem-alone arm, although it did not
reach statistical signiﬁcance [median 9.4 versus 7.1 months; HR
0.84 (95% CI 0.56–1.27); P = 0.404].
Volume 27 | No. 4 | April 2016 doi:10.1093/annonc/mdw006 | 
Annals of Oncology original articles
 at U
niversity of M
assachusetts M
edical School on O
ctober 12, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
An evaluation of discrete, nonoverlapping subsets at week 8
revealed that a ≥60% to <90% decrease in CA19-9 from baseline
was a predictor for the longest OS in both treatment groups
(nab-P + Gem n = 87, median OS 14.3 months, and Gem-alone
n = 61, median OS 10.4 months, Table 4).
predictive and prognostic value of CA19-9 kinetics
over time
A steep decline in CA19-9 levels was observed in each of the two
treatment arms during the ﬁrst 8 weeks of treatment, with a
plateau after week 16 (Figure 2). A steeper velocity of decline in
CA19-9 levels during the ﬁrst 8 weeks generally correlated with
improved OS, PFS, and conﬁrmed ORR (supplementary
Table S3, available at Annals of Oncology online) for the two
treatment arms. In the nab-P + Gem arm, patients in the top
(≥17.7% decrease/week) and middle (7% to <17.7% decrease/
week) versus the lowest tertile of velocity (<7% decrease/week)
had better outcomes (median OS, 13.4 and 13.2 versus 8.3
months; median PFS, 8.5 and 7.6 versus 5.9 months; ORR, 51%
and 29% versus 19%, supplementary Table S3, available at
Annals of Oncology online). The trend was not as evident in the
Gem-alone arm (supplementary Table S3, available at Annals of
Oncology online).
radiologic response by week 8 and outcomes
The correlations between achieving a RECIST-deﬁned radio-
logic response [unconﬁrmed complete response (CR) or partial
response (PR)] by week 8 and OS were examined for the CA19-
9–assessable patients. A CR or PR was achieved in 16% (40/252)
of patients in the nab-P + Gem arm and 6% (13/202) of patients
in the Gem-alone arm by week 8. Thirty-eight of the 40 patients
in the nab-P + Gem arm and all 13 patients in the Gem-alone
arm with CR/PR had a decrease in CA19-9 at week 8. The
median OS for patients with a radiologic response was 13.7 and
14.7 months, respectively.
Most CA19-9 assessable patients had unconﬁrmed stable
disease (SD) by week 8: 79% (199/252) and 84% (170/202) in
the nab-P + Gem and Gem-alone arms, respectively, with corre-
sponding median OS of 11.1 and 9.0 months. Among patients
with SD, 79% (158/199) in the nab-P + Gem arm and 78% (133/
170) in the Gem-alone arm had a CA19-9 decrease at week 8,
with corresponding median OS of 13.2 and 9.4 months, respect-
ively. Median OS for SD patients without CA19-9 decrease at
week 8 was 8.3 and 7.1 months, respectively.
discussion
This analysis demonstrated that any decrease in CA19-9 level at
week 8—which occurred in 82% and 79% of 454 overall assess-
able patients treated with nab-P + Gem and Gem-alone, respect-
ively—was associated with improved outcomes, representing a
valuable tool for early prediction of treatment beneﬁt. CA19-9
decrease versus no decrease correlated with larger survival
Table 2. Correlation between CA19-9 decrease from baseline to
week 8 and OS: pooled analysis
Change in CA19-9
from baseline
Patients with the
specified decrease
Patients without
the specified
decrease
P
valuea
n Median OS
(months)
n Median OS
(months)
Any decrease 365 11.1 89 8.0 0.005
≥20% decrease 338 11.1 116 8.2 0.004
≥60% decrease 241 11.9 213 8.5 <0.001
≥90% decrease 93 11.1 361 9.7 0.189
aP value based on a log-rank test stratified by geographic region
(Australia versus Eastern Europe versus North America versus Western
Europe), Karnofsky performance status (70–80 versus 90–100), and the
presence of liver metastases (yes versus no).
OS, overall survival.
Table 1. Summary of baseline CA19-9 levels and change in CA19-9 levels from baseline at week 8
CA19-9 variables nab-P + Gem
(N = 431)a
Gem
(N = 430)a
Patients with a baseline measurement, n 379 371
Baseline median, U/ml (min, max) 2294 (2, 6 159 233) 2759 (0, 12 207 654)
≥200 U/ml at baseline, n (%) 282 (74) 275 (74)
≥1000 U/ml at baseline, n (%) 228 (60) 220 (59)
Patients with baseline and week-8 measurements (landmark), n 252 202
Changeb from baseline at week 8, median (min, max), % −70 (−100, 1230) −57 (−100, 1 43 268)
Category of change from baseline at week 8, n (%)
No change or any increase 46 (18) 43 (21)
Any decrease 206 (82) 159 (79)
≥20% decrease 197 (78) 141 (70)
≥60% decrease 146 (58) 95 (47)
≥90% decrease 59 (23) 34 (17)
aPatients in the intention-to-treat population.
bNegative % change means decrease in CA19-9.
Gem, gemcitabine; nab-P, nab-paclitaxel.
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Table 3. Efficacy summary by category of CA19-9 changes from baseline to week 8
Decreases in CA19-9 level n nab-P + Gem n Gem RRR or HR P valuea
Any decrease (>0%)
ORR (%) 206 40 159 15 2.64 <0.001
PFS, median (months)b 193 7.7 139 5.6 0.66 0.005
OS, median (months) 206 13.2 159 9.4 0.60 <0.001
1-year survival rate (%) 206 53 159 35 – –
No change or any increase
ORR (%)c 46 13 43 5 2.80 0.167
PFS, median (months)b 42 5.5 34 5.2 0.91 0.777
OS, median (months) 46 8.3 43 7.1 0.96 0.885
1-year survival rate (%) 46 27 43 22 – –
OS HRd 0.53 0.84 –
95% CI 0.36–0.78 0.56–1.27
P value 0.001 0.404
Decrease ≥20%
ORR (%)c 197 40 141 17 2.36 <0.001
PFS, median (months)b 187 7.7 125 5.7 0.66 0.007
OS, median (months) 197 13.2 141 9.4 0.59 <0.001
1-year survival rate (%) 197 53 141 34 – –
Decrease <20%
ORR (%)c 55 16 61 3 4.99 0.016
PFS, median (months)b 48 5.9 48 4.4 0.78 0.426
OS, median (months) 55 8.3 61 8.0 0.95 0.819
1-year survival rate (%) 55 30 61 27 – –
OS HRd 0.55 0.85 –
95% CI 0.38–0.78 0.59–1.23
P value 0.001 0.396
Decrease ≥60%
ORR (%)c 146 45 95 23 1.95 0.001
PFS, median (months)b 142 9.0 87 6.2 0.63 0.017
OS, median (months) 146 14.2 95 9.8 0.55 <0.001
1-year survival rate (%) 146 58 95 37 – –
Decrease <60%
ORR (%)c 106 21 107 4 5.55 <0.001
PFS, median (months)b 93 5.8 86 5.2 0.84 0.368
OS, median (months) 106 8.7 107 8.0 0.81 0.183
1-year survival rate (%) 106 35 107 28 – –
OS HRd 0.54 0.69 –
95% CI 0.39–0.73 0.50–0.97
P value <0.001 0.033
Decrease ≥90%
ORR, %c 59 63 34 35 1.78 0.011
PFS, median (months)b 58 8.5 33 5.6 0.44 0.006
OS, median (months) 59 13.4 34 9.8 0.47 0.005
1-year survival rate (%) 59 57 34 23 – –
Decrease <90%
ORR, %c 193 26 168 8 3.17 <0.001
PFS, median (months)b 177 6.7 140 5.5 0.81 0.155
OS, median (months) 193 10.8 168 8.9 0.73 0.013
1-year survival rate (%) 193 45 168 35 – –
OS HRd 0.75 0.95 –
95% CI 0.52–1.09 0.62–1.45
P value 0.132 0.812
aBetween-treatment arm P values were based on a χ2 test for ORR, or a stratified log-rank test for OS and PFS. The associated HR and 95% CI were
estimated using a stratified Cox model for OS and PFS. Stratification was not applied for OS and PFS if the number of patients was <50 in either arm.
bPFS measure excludes patients with a date of disease progression before week 8.
cConfirmed ORR by RECIST.
dWithin-treatment arm P values for the indicated comparison were based on a stratified log-rank test for OS. The associated HR and 95% CI were
estimated using a stratified Cox model for OS. Stratification was not applied for OS if the number of patients was <50 in either arm.
Gem, gemcitabine; HR, hazard ratio; nab-P, nab-paclitaxel; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RECIST,
Response Evaluation Criteria In Solid Tumors; RRR, relative response rate.
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beneﬁt with nab-P + Gem {4.9 months improvement in median
OS [13.2 versus 8.3 months; HR 0.53 (95% CI 0.36–0.78);
P = 0.001]} compared with Gem alone [2.3 months of improve-
ment in median OS (9.4 versus 7.1 months); HR 0.84 (95% CI
0.56–1.27); P = 0.404]. The robust predictive value of a week-8
CA19-9 decrease with nab-P + Gem is particularly relevant as
this regimen is widely used and has become one of the standard
ﬁrst-line treatments for metastatic pancreatic cancer.
A recent retrospective analysis of the phase III ACCORD11/
PRODIGE4 study also reported a correlation between CA19-9
decreases and improved efﬁcacy outcomes in 160 overall assess-
able patients treated with FOLFIRINOX or Gem alone [19]. In
the pooled population, a CA19-9 decrease of ≥20% versus <20%
at week 8 signiﬁcantly correlated with longer OS (median 10.3
versus 7.8 months; HR 0.57 [95% CI 0.40–0.81]; P = 0.002),
whereas in the FOLFIRINOX and Gem-alone arms, a CA19-9
decrease of ≥20% was observed in 59% and 52% of patients, re-
spectively, and associated with a median OS of 13.5 and 8.6
months, respectively (P = 0.021). Our data similarly show that a
week-8 CA19-9 decrease is predictive of superior efﬁcacy out-
comes and that nab-P + Gem is more likely than Gem alone to
achieve these results. In the intention-to-treat (ITT) population
of MPACT, the ﬁnal median OS was 8.7 months in the nab-
P + Gem arm (n = 431) [15]. Patients in this treatment arm who
achieved any CA19-9 decrease at week 8 (n = 206) had a median
OS of 13.2 months. Likewise, the median OS in the ITT popula-
tion in the Gem-alone arm (n = 430) was 6.6 months, and in
patients with any CA19-9 decrease (n = 159), the median OS
was 9.4 months. Thus, achieving any reduction in CA19-9 was
an indicator of OS beneﬁt in both treatment arms.
The treatment beneﬁt of nab-P + Gem was predicted early, at
week 8, by CA19-9 decline, whereas the Kaplan–Meier survival
curves did not begin to show a beneﬁt for nab-P + Gem versus
Gem alone until later, at ≈5 months, when the OS curves begin
to separate for every cutoff of CA19-9 decrease (Figure 1). This
observation was also noted for the ITT population of MPACT
[14]. Although larger decreases in CA19-9 appeared to associate
with higher ORRs (Table 3), the association with OS seemed
less pronounced. However, the majority of patients with ‘any’
CA19-9 decrease (66%, 241/365) had in fact a ≥60% decrease in
CA19-9, and this patient cohort had the longest OS (14.2
months), which likely inﬂuenced the overall OS in the nab-
P + Gem arm (Tables 3 and 4). Nevertheless, the overall ﬁndings
of this study suggest that any CA19-9 decrease at week 8 may
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Figure 1. OS in patients with any, ≥20%, ≥60%, and ≥90% CA19-9 level decreases from baseline at week 8. Kaplan–Meier survival curves for patients with
any (A), ≥20% (B), ≥60% (C), and ≥90% (D) reductions in CA19-9 level from baseline at week 8. Gem, gemcitabine; HR, hazard ratio; nab-P, nab-paclitaxel.
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have relevance as an early surrogate for outcome in future
clinical trials.
A higher proportion of patients treated with nab-P + Gem
versus Gem alone had a steeper decrease in CA19-9 during the
ﬁrst 8 weeks. The top two velocity tertiles were associated with a
nearly 5-month longer OS versus the lower tertile for nab-
P + Gem, while less beneﬁt was observed within the Gem-alone
group (≈1-month longer OS for the top two velocity tertiles
versus the lower tertile). Achieving a reduction in CA19-9 at a
greater velocity may be an additional marker of early treatment
efﬁcacy, especially for treatment with nab-P + Gem.
Although 82% of assessable patients in the nab-P + Gem arm
had any CA19-9 decrease at week 8 with an associated median
OS of 13.2 months, only 16% of patients in this arm met RECIST
criteria for unconﬁrmed radiologic response at week 8 with an
associated median OS of 14 months. In addition, 62% of patients
had SD by RECIST criteria and a decrease in CA19-9 with a
median OS of 13.2 months. In the Gem-alone arm, patients with
an unconﬁrmed RECIST response (6%) had the longest OS
(median 15 months), while 79% of patients had a CA19-9 de-
crease (median OS 9.4 months). Patients with SD and any CA19-
9 decrease at week 8 (66%) also had a median OS of 9.4 months.
Particularly in the nab-P + Gem arm, the median OS of patients
with RECIST response or any CA19-9 decrease at week 8 seemed
comparable, and furthermore, patients with SD and any CA19-9
decrease had similarly improved survival. These results suggest
that a week-8 CA19-9 decline may be a more sensitive early pre-
dictor of survival than RECIST response.
CA19-9 evaluations coincided with radiologic assessments,
which occurred every 8 weeks. Thus, a limitation of this study
was that the ﬁrst CA19-9 evaluation was not made until week
8. Future prospective studies should evaluate if CA19-9 is also
prognostic at earlier time points.
In conclusion, this analysis supports the utility of CA19-9 as
an early marker for antitumor activity in patients with metastat-
ic pancreatic cancer and demonstrates that any degree of reduc-
tion in CA19-9, as well as the kinetics of decline in CA19-9
levels, are important indicators of treatment beneﬁt, particularly
with the nab-P + Gem regimen.
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Table 4. Subgroup analysis of OS based on CA19-9 change at week 8
Change in CA19-9 level at
week 8
nab-P + Gem
(n = 252)
Gem
(n = 202)
Decrease
≥90%, n 59 34
OS, median (months) 13.4 9.8
≥60% to <90%, n 87 61
OS, median (months) 14.3 10.4
≥40% to <60%, n 36 27
OS, median (months) 10.5 7.9
≥20% to <40%, n 15 19
OS, median (months) 8.1 8.4
>0% to <20%, n 9 18
OS, median (months) 10.5 9.0
Increase
0% to ≤20%, n 11 12
OS, median (months) 8.7 7.1
>20% to ≤40%, n 9 12
OS, median (months) 9.2 6.9
>40%, n 26 19
OS, median (months) 8.1 6.1
Gem, gemcitabine; nab-P, nab-paclitaxel; OS, overall survival.
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Figure 2. Decrease from baseline over time (velocity) in CA19-9 level for
evaluable patients on study treatment. CA19-9 levels were measured at base-
line and every 8 weeks. Gem, gemcitabine; nab-P, nab-paclitaxel.
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A randomized clinical trial of neoadjuvant chemotherapy
versus neoadjuvant chemoradiotherapy for cancer of
the oesophagus or gastro-oesophageal junction
F. Klevebro1*, G. Alexandersson von Döbeln2, N. Wang3, G. Johnsen4, A.-B. Jacobsen5,
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Background: Neoadjuvant therapy improves long-term survival after oesophagectomy, treating oesophageal
cancer, but the evidence to date is insufﬁcient to determine which of the two main neoadjuvant therapy types, chemo-
therapy (nCT) or chemoradiotherapy (nCRT), is more beneﬁcial. We aimed to compare the effects of nCT with those of
nCRT.
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